

was generated using SuperScript RNase H reverse transcriptase (Gibco/BRL) and a primer complimentary to a sequence in the 3'-untranslated region of the human GRP78/BiP mRNA transcript (AB10230; 5'-TATTACAGCACTAGCAGATCAGTG-3') (SEQ ID NO:1). For PCR amplification, the forward primer AB10231 (5'-CTTAAGCTTGCCACCATGAAGCTCTCCCTGGTGGCCGCG-3') (SEQ ID NO:2) contained a Kozak consensus sequence (bold) prior to the initiating ATG and a terminal *Hind*III restriction site (underlined). The reverse primer AB10232 (5'-AGGCCTCGAGCTACAACATCATCTTTTCTGCTGT-3') (SEQ ID NO:3) contained a terminal *Xho*I restriction site (underlined) adjacent to the authentic termination codon of the GRP78/BiP cDNA. PCR reactions took place in a final volume of 50 µl containing 2 µl of the RT reaction, 100 ng of primers, 2.5 U *Taq* polymerase (Perkin-Elmer, Mississauga, ON) in a buffer consisting of 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, 10 mM Tris-HCl (pH 8.8) and 0.5 mM of each dNTP. All samples were subjected to amplification in a DNA thermal cycler 480 (Perkin-Elmer) with a step programme of 30 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 1 min. The amplified GRP78/BiP cDNA was separated on a 0.8% agarose-TBE gel containing ethidium bromide, purified from the agarose gel using the QIAEX gel extraction kit (Qiagen, Mississauga, ON) and ligated into T-ended pBluescript (KS) (Stratagene, La Jolla, CA). The ligation mixture was then used to transform competent DH5α cells (Gibco/BRL). Plasmid DNA was isolated from transformed cells using the QIAEX miniprep kit (Qiagen), digested with *Hind*III and *Xho*I, and the GRP78/BiP cDNA insert purified from agarose. The GRP78/BiP cDNA insert was ligated into the *Hind*III/*Xho*I site of the mammalian expression vector pcDNA3.1(+) (Invitrogen, Carlsbad, CA) to produce the recombinant plasmid, pcDNA3.1(+)-GRP78/BiP. Authenticity of the GRP78/BiP cDNA sequence was confirmed by fluorescence-based double stranded DNA sequencing (MOBIX).

(NE page 46 is missing)  
Please replace the paragraph beginning at page 46, line 3, with the following rewritten paragraph:

**SEQ ID NO:4**

Human GRP78/BiP amino acid sequence

MKLSLVAAMLLLLSAARAEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIA  
NDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDKRLIGRTWNDPSVQ  
QDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETA EAYLGKK

a2  
VTHAVVTVPAYFNDAQRQATK DAGTIAGLNVMRIINEPTAAAIA YGLDKREGEK  
NILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRM EHFILYKK  
KTGKDVRKDNRAVQKLRREVEKAKRALSSQH QARIEIESFYEGEDFSETLTRAKF  
EELNMDLFRSTMKPVQKVLESDLKKS DIDEIVLVGGSTRIPKIQQLVKEFFNGK  
EPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKL  
IPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRG  
VPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFA  
EEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSSEDKETMEKAVEEKIE  
WLESHQDADIEDFKAKKKELE EIVQPIISKLYGSAGPPPTGEEDTAEKDEL

Please replace the paragraph beginning at page 46, line 20, with the following  
rewritten paragraph:

**SEQ ID NO: 5**

Human GRP78/BiP mRNA sequence

a3  
1 ACTGGCTGGC AAGATGAAGC TCTCCCTGGT GGCCGCGATG CTGCTGCTGC TCAGCGCGGC  
61 GCGGGCCGAG GAGGAGGACA AGAAGGAGGA CGTGGGCACG GTGGTCGGCA TCGACCTGGG  
121 GACCACCTAC TCCTGCGTCG GCGTGTTC AAACGGCCGC GTGGAGATCA TCGCCAACGA  
181 TCAGGGCAAC CGCATCACGC CGTCTATGT CGCCTTCACT CCTGAAGGGG AACGTCTGAT  
241 TGGCGATGCC GCCAAGAACC AGCTCACCTC CAACCCCGAG AACACGGTCT TTGACGCCAA  
301 GCGGCTCATC GGCCGCACGT GGAATGACCC GTCTGTGCAG CAGGACATCA AGTTCTTGCC  
361 GTTCAAGGTG GTTGAAAAGA AAATAAACC ATACATTCAA GTTGATATTG GAGGTGGGCA  
421 AACAAAGACA TTTGCTCCTG AAGAAATTC TGCCATGGTT CTCACTAAAA TGAAAGAAAC  
481 CGCTGAGGCT TATTTGGGAA AGAAGTTAC CCATGCAGTT GTTACTGTAC CAGCCTATTT  
541 TAATGATGCC CAACGCCAAG CAACCAAAGA CGCTGGA ACTTGCTGGCC TAAATGTTAT  
601 GAGGATCATC AACGAGCCTA CGGCAGCTGC TATTGCTTAT GGCCTGGATA AGAGGGAGGG  
661 GGAGAAGAAC ATCCTGGTGT TTGACCTGGG TGGCGGAACC TTCGATGTGT CTCTTCTCAC  
721 CATTGACAAT GGTGTCTTCG AAGTTGTGGC CACTAATGGA GATACTCATC TGGGTGGAGA  
781 AGACTTTGAC CAGCGTGTCA TGGAACACTT CATCAA ACTG TACAAAAAGA AGACGGGCAA  
841 AGATGTCAGG AAAGACAATA GAGCTGTGCA GAAACTCCG CGCGAGGTAG AAAAGGCCAA  
901 ACGGGCCCTG TCTTCTCAGC ATCAAGCAAG AATTGAAATT GAGTCCTTCT ATGAAGGAGA  
961 AGACTTTTCT GAGACCCTGA CTCGGGCCAA ATTTGAAGAG CTCAACATGG ATCTGTTCCG  
1021 GTCTACTATG AAGCCCGTCC AGAAAGTGTT GGAAGATTCT GATTGAAGA AGTCTGATAT  
1081 TGATGAAATT GTTCTTGTTG GTGGCTCGAC TCGAATTCCA AAGATT CAGC AACTGGTTAA  
1141 AGAGTTCTTC AATGGCAAGG AACCATCCCG TGGCATAAAC CCAGATGAAG CTGTAGCGTA  
1201 TGGTGCTGCT GTCCAGGCTG GTGTGCTCTC TGGTGATCAA GATACAGGTG ACCTGGTACT  
1261 GCTTGATGTA TGTCCCTTA CACTTGGTAT TGAAACTGTG GGAGGTGTCA TGACCAA ACT